Certolizumab pegol (Cimzia®)

Assessment Status NCPE Assessment Process complete
Drug Certolizumab pegol
Brand Cimzia®
Indication For the treatment of moderate to severe rheumatoid arthritis.
Assessment Process
Full submission received from Applicant 13/03/2010
NCPE assessment completed 02/09/2010
NCPE assessment outcome Reimbursement not Recommended.

The review group did not consider certolizumab cost-effective at the submitted price in September 2010.

The HSE has approved reimbursement following confidential price negotiations.

Technical Summary